MOUNTAIN VIEW, Calif. & BRANFORD, Conn.--(BUSINESS WIRE)--Perlegen Sciences, Inc., and 454 Life Sciences, part of Roche Diagnostics, announced today a collaboration to conduct large scale genetic re-sequencing in hundreds of human DNA samples collected by Perlegen from individuals with specific responses to a widely prescribed class of drug. The goal of the collaboration will be to determine whether sufficient genetic variation can be identified and validated to create a clinical test that will predict how individuals might respond to this class of medicines.
